The Global Regulatory Landscape for Psychedelics

Forty-odd jurisdictions have moved on psychedelics regulation in some form since 2020. That's not opinion; it's a count you can run through the relevant legislative databases yourself. What that number hides is how different those moves have been, and that is the heart of the global regulatory landscape. A city decriminalising personal possession is not the same thing as a national health authority rescheduling a compound for supervised prescriber use. Conflating the two is where a lot of public conversation goes wrong, and it's worth being precise.

The precision matters most for Australian readers, because the legal position in this country is specific and consequential. Reading the primary documents, rather than a summary of a summary, is the only dependable way to follow it.

Where Australia actually stands

Let's start with the domestic picture, because it is the only one that governs you if you're in Australia.

Psilocybin (the active compound in psilocybe mushrooms) and MDMA are listed under Schedule 9 of the Poisons Standard, the Prohibited Substances schedule, the most restrictive category in Australian scheduling law. Possession, manufacture, supply or use outside of a lawfully authorised framework is a criminal offence under state and territory legislation. That position has not changed.

What did change on 1 July 2023 was a narrow, tightly defined exception. The TGA amended the Poisons Standard to permit Authorised Prescribers; psychiatrists approved under the Therapeutic Goods Administration's Authorised Prescriber scheme, to prescribe psilocybin (rescheduled to Schedule 8 in this specific context) for treatment-resistant depression, and MDMA (also Schedule 8 in context) for post-traumatic stress disorder. Outside that pathway, both substances remain Schedule 9. The background to that decision is covered in the 2023 down-scheduling of psilocybin.

Schedule 8 means controlled drug status: strict record-keeping, specific prescribing and dispensing rules, and oversight mechanisms that differ by state. It is not a general prescription category. The Special Access Scheme (SAS) provides a separate, case-by-case pathway for unapproved therapeutic goods, including for substances not yet on the Australian Register of Therapeutic Goods (ARTG). Neither pathway authorises general patient access or self-directed use. If a product isn't prescribed to you through one of these formal channels, it is not legal for you to have it.

The TGA's own published guidance makes this clear, as does the ADF's summary of psychedelic scheduling in Australia. If you want the regulator's role laid out first, the TGA explained is a sensible starting point.

Why state and federal layers both matter

A common mistake is to treat "the law" on psychedelics as a single rulebook. In Australia it is layered. The Poisons Standard sets the national scheduling category, but the offences for possession, supply and manufacture sit in state and territory legislation, and each jurisdiction applies the schedules through its own statutes. That is why oversight mechanisms for Schedule 8 substances differ by state, and why a reform in one place can look quite different from the same reform somewhere else.

When you read a news item about a change, ask which layer it touches. A scheduling amendment alters the national category. A state decriminalisation measure alters how a possession offence is handled locally. Neither automatically changes the other. For a fuller treatment of how the layers interact, see state versus federal drug regulation in Australia.

The research context, and its limits

The scheduling change followed years of clinical research, mostly from overseas institutions but increasingly from Australian sites. Trials at institutions including St Vincent's Hospital in Melbourne and the Mind Medicine Australia–supported programmes generated data the TGA weighed in its rescheduling decision. It's worth being honest about what that research does and doesn't show.

Published trials; including the phase 2 data in NEJM Evidence (2022) examining psilocybin versus a selective serotonin reuptake inhibitor, reported statistically significant outcomes on depression rating scales in controlled, supervised settings with screened participants. But sample sizes were small (the NEJM Evidence trial had 59 participants), follow-up periods were often short, adverse event monitoring was intensive, and participant populations were not representative of the general public. Researchers themselves have called for larger, longer, more diverse trials before drawing firm conclusions. That context tends to get lost in popular coverage.

Small samples matter because a result that looks striking in a few dozen carefully screened people can shrink or change when the group gets bigger and more varied. Short follow-up matters because it says little about how long any observed change lasts. And intensive monitoring, while good for safety in a trial, describes conditions that ordinary life does not replicate.

In my view, the common error is assuming "promising results" translate more directly to "established evidence base" than the trial methodologies warrant. The short version is: the signal is interesting, the evidence base is still developing, and the regulatory decisions made so far reflect supervised research conditions, not general use.

How other jurisdictions have approached this

The United States federal position lists psilocybin as a Schedule I controlled substance under the Controlled Substances Act; meaning no currently accepted medical use and high potential for abuse in the federal framework. That has not changed. But below federal level, Oregon passed Measure 109 in 2020, establishing a licensed service centre model under the Oregon Psilocybin Services Act (effective 2023) that permits supervised psilocybin use for adults in approved facilities, not as a prescription medicine, but as a regulated "service." Colorado followed in 2022 with Proposition 122. These are state-level regulated access models, not federal legalisation, and they do not affect how the FDA classifies the compound.

The FDA has granted psilocybin Breakthrough Therapy designation, twice, for different indications; which expedites the review process but does not constitute approval. No psilocybin product is FDA-approved as of this writing.

In Canada, Health Canada's Special Access Programme was amended in 2022 to allow certain practitioners to request psilocybin and MDMA for patients with serious conditions where conventional treatments have failed, a framework that looks structurally similar to Australia's SAS pathway. Switzerland has run compassionate use exceptions for some years under its specific cantonal rules.

The Netherlands occupies a different position: psilocybin (the isolated compound) is listed under the Opium Act, but psilocybe truffles occupy a legal grey area that has produced a well-documented commercial "truffle ceremony" industry. This is frequently mischaracterised as legalisation. It is not; it is an unresolved scheduling inconsistency, and Dutch authorities have periodically signalled they may address it.

Jamaica has no specific law prohibiting psilocybin mushrooms, the compound itself is not scheduled there; which has led to the growth of a retreat industry. The legal basis there is essentially the absence of prohibition rather than affirmative authorisation. A meaningful distinction.

The pattern across these examples is that the label on a policy tells you little. What counts is who is authorised, in what setting, for which purpose, and under whose oversight. The same word, "access", can describe a clinician-led request for an individual patient in one country and a licensed facility model in another.

The mechanisms researchers are studying

Separate from the law, the neuroscience is worth understanding on its own terms. Psilocybin is a prodrug: after ingestion it is converted to psilocin, which acts primarily as a serotonin 5-HT2A receptor agonist. The 5-HT2A receptor is structurally and functionally distinct from the receptors of the endocannabinoid system, though both receptor families are subject to active pharmacological research. Psilocin's binding at 5-HT2A (and to a lesser extent 5-HT2C and other serotonin receptors) is associated with the perceptual and cognitive alterations characteristic of classical psychedelics. Researchers are also examining downstream effects on default mode network connectivity, neuroplasticity markers, and BDNF expression.

Understanding pharmacokinetics is relevant here too: psilocybin is rapidly dephosphorylated to psilocin, which has a relatively short plasma half-life but produces effects lasting several hours. Dosing in clinical trials is weight-adjusted and administered in controlled environments with trained support staff. The specific doses used in published trials are reported in those papers as study parameters, they are not instructions for use, and replicating trial conditions outside a supervised clinical setting is not possible.

Terms like "agonist" and "prodrug" are descriptive, not promotional. They explain what a compound does at a receptor and how the body processes it, and they say nothing about whether any use is safe, appropriate or lawful. Mechanism research is also an early step; a plausible mechanism does not on its own establish that a substance is effective for anything.

Decriminalisation versus legalisation: a distinction that matters

Several Australian jurisdictions and overseas cities have decriminalised personal possession of small amounts of certain substances. The ACT's 2023 drug decriminalisation reforms, for instance, moved simple personal possession of a range of substances (within defined thresholds) from a criminal to a civil infringement matter, though supply, manufacture, and trafficking remain criminal. This is not legalisation. Decriminalisation removes or reduces criminal penalties for possession; it does not create a legal supply chain, does not authorise use, and does not change the scheduling status of the substance under the Poisons Standard.

Honestly, the conflation of these terms in media coverage does a disservice to public understanding. They represent genuinely different policy positions with different practical consequences.

Portugal's much-cited decriminalisation model (2001, covering all substances) operates similarly: possession up to a ten-day personal supply triggers an administrative hearing before a Dissuasion Commission rather than criminal prosecution, but production and supply remain criminal offences. It is a harm-reduction policy instrument, not a legalisation framework.

A quick test helps when you meet a headline. Ask whether the change creates a lawful way to produce and supply the substance, or only changes the penalty attached to possessing it. If it is the second, it is decriminalisation. Ask too whether the scheduling status has moved. Anyone wanting to see how scheduling decisions have shifted over time can look at a timeline of Australian drug scheduling.

What the global regulatory landscape actually tells us

No country has fully legalised classical psychedelics in the way, say, Canada legalised cannabis federally in 2018. What exists is a patchwork: supervised clinical or service-centre models, narrow prescriber pathways, compassionate access schemes, decriminalisation of possession in some places, and scheduling anomalies in others. Australia's 2023 change sits within that patchwork, a tightly scoped prescriber pathway, not open access.

For researchers, the regulatory environment is genuinely shifting. For general members of the public in Australia, the position is unambiguous: psilocybin and MDMA are Schedule 9 prohibited substances unless accessed through the specific TGA-authorised prescriber framework. There is no other legal route. For more on why going outside that framework is a problem, see why self-medicating with psilocybin is illegal in Australia.

Advertising adds a further layer. Therapeutic goods advertising in Australia is tightly controlled, so claims about psychedelic substances are limited well beyond the scheduling rules; advertising rules for therapeutic goods explains the framework.

Watch this space. But watch it carefully, and watch the actual legislative documents; not the headlines.

Sources

• TGA authorises prescribed use of psilocybin and MDMA, Therapeutic Goods Administration (TGA)
• Psilocybin drug facts, Australian Drug Foundation (ADF)
• Trial of Psilocybin versus Escitalopram for Depression; NEJM Evidence (Carhart-Harris et al., 2021)
• Classic Hallucinogens and Mystical Experiences: Pharmacology and Cultural Context, NCBI/NIH

Daniel Okoro, Psychedelic science & law writer